22057 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Hudis
    Hudis
  4. Kris
    Kris
  5. Saltz
    Saltz
  6. Offit
    Offit
  7. O'Reilly
    O'Reilly
  8. Solit
    Solit
  9. Robson
    Robson
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)
  7. Breast Medicine Service (4103)
  8. Surgery (4019)
  9. Department of Pathology and Laboratory Medicine (3422)
  10. Thoracic Oncology (3351)
  1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic characterization of ERBB2-driven biliary cancer and a case of response to ado-trastuzumab emtansine
    Journal Article

    Mondaca, S.; Razavi, P.; Xu, C.; Offin, M.; Myers, M.; Scaltriti, M.; Hechtman, J. F.; Bradley, M.; O'Reilly, E. M.; Berger, M. F.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Pathogenic loss-of-function germline TERT mutations in patients with solid tumors
    Journal Article

    Walsh, M. F.; Sacca, R.; Wildman, T.; Amoroso, K.; Kennedy, J.; Zhang, L.; Birsoy, O.; Mandelker, D.; Steinsnyder, Z.; Latham, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using EndoPredict, an integrated 12-gene clinicomolecular assay
    Journal Article

    Soliman, H.; Flake, D. D. 2nd; Magliocco, A.; Robson, M.; Schwartzberg, L.; Sharma, P.; Brown, K.; Wehnelt, S.; Kronenwett, R.; Gutin, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • VATS can be used to effectively triage women with ovarian cancer and moderate to large pleural effusions to PDS or NACT/IDS
    Meeting Abstract

    Filippova, O.; Bharathan, R.; Cowan, R.; Lakhman, Y.; Tew, W.; O'Cearbhaill, R.; Konner, J.; Park, B.; Huang, J.; Gardner, G.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: Efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the phase III SOLO1 trial
    Meeting Abstract

    Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: An analysis from the phase 3 study ARIEL3
    Meeting Abstract

    Clamp, A. R.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: Post hoc exploratory analyses by BRCA mutation status and patient age
    Meeting Abstract

    Colombo, N.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study
    Meeting Abstract

    Gonzalez-Martin, A.; Pothuri, B.; Vergote, I.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy
    Meeting Abstract

    Leung, J.; Rojas, L. A.; Ruan, J.; Zhao, J.; Gasmi, B.; Sethna, Z.; Ramnarain, A.; Bhanot, U.; Askan, G.; Gururajan, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
    Meeting Abstract

    Engle, D.; Tiriac, H.; Rivera, K.; Pommier, A.; Whalen, S.; Oni, T.; Alagesan, B.; Lee, E.; Yao, M.; Lucito, M.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save